Alnylam Starts Liver Cancer Trial
Luke Timmerman4/3/09
Alnylam Pharmaceuticals (NASDAQ: ALNY), the Cambridge, MA-based developer of RNA interference drug technology, said today it has started an early-phase clinical trial of a treatment for liver cancer. The trial is important because it is Alnylam’s first attempt to make an RNAi drug that can circulate throughout the body, as CEO John Maraganore explained in this interview in December. The trial will enroll 55 patients with liver cancer in the U.S.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
